MA33923B1 - Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a - Google Patents
Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10aInfo
- Publication number
- MA33923B1 MA33923B1 MA35064A MA35064A MA33923B1 MA 33923 B1 MA33923 B1 MA 33923B1 MA 35064 A MA35064 A MA 35064A MA 35064 A MA35064 A MA 35064A MA 33923 B1 MA33923 B1 MA 33923B1
- Authority
- MA
- Morocco
- Prior art keywords
- present
- formula
- relates
- subject
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention a pour objet des composés (Formule 1) qui sont des inhibiteurs de l'enzyme PDE10A. La présente invention concerne une composition pharmaceutique comprenant une quantité thérapeutiquement efficace d'un composé selon l'invention et un véhicule pharmaceutiquement acceptable. La présente invention concerne également des procédés pour la préparation des composés de formule (I). La présente invention concerne en outre une méthode de traitement d'un sujet souffrant d'un trouble neurodégénératif comprenant l'administration au sujet d'une quantité thérapeutiquement efficace d'un composé de formule (I). La présente invention concerne également une méthode de traitement d'un sujet souffrant d'une pharmacodépendance comprenant l'administration au sujet d'une quantité thérapeutiquement efficace d'un composé de formule (I). La présente invention concerne en outre une méthode de traitement d'un sujet souffrant d'un trouble psychiatrique comprenant l'administration au sujet d'une quantité thérapeutiquement efficace d'un composé de formule (I).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28732109P | 2009-12-17 | 2009-12-17 | |
| DKPA200901340 | 2009-12-17 | ||
| PCT/DK2010/050344 WO2011072697A1 (fr) | 2009-12-17 | 2010-12-15 | Dérivés hétéroaromatiques d'aryltriazole en tant qu'inhibiteurs de l'enzyme pde10a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33923B1 true MA33923B1 (fr) | 2013-01-02 |
Family
ID=44246811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA35064A MA33923B1 (fr) | 2009-12-17 | 2010-12-15 | Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US8501795B2 (fr) |
| EP (1) | EP2513106B1 (fr) |
| JP (1) | JP6035149B2 (fr) |
| KR (1) | KR101779629B1 (fr) |
| CN (1) | CN102753550B (fr) |
| AR (1) | AR079496A1 (fr) |
| AU (1) | AU2010333438B2 (fr) |
| BR (1) | BR112012014486A2 (fr) |
| CA (1) | CA2783728C (fr) |
| CO (1) | CO6602117A2 (fr) |
| CR (1) | CR20120318A (fr) |
| CY (1) | CY1116361T1 (fr) |
| DK (1) | DK2513106T3 (fr) |
| DO (1) | DOP2012000169A (fr) |
| EA (1) | EA021606B1 (fr) |
| ES (1) | ES2442179T3 (fr) |
| GE (1) | GEP20146201B (fr) |
| GT (1) | GT201200193A (fr) |
| HK (1) | HK1177745A1 (fr) |
| HR (1) | HRP20131210T1 (fr) |
| IL (1) | IL220328A (fr) |
| MA (1) | MA33923B1 (fr) |
| MX (1) | MX2012006715A (fr) |
| MY (1) | MY156520A (fr) |
| NZ (1) | NZ600365A (fr) |
| PL (1) | PL2513106T3 (fr) |
| PT (1) | PT2513106E (fr) |
| RS (1) | RS53101B (fr) |
| SG (1) | SG181672A1 (fr) |
| SI (1) | SI2513106T1 (fr) |
| SM (1) | SMT201400009B (fr) |
| TN (1) | TN2012000278A1 (fr) |
| TW (1) | TWI487705B (fr) |
| UA (1) | UA107950C2 (fr) |
| WO (1) | WO2011072697A1 (fr) |
| ZA (1) | ZA201204420B (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI487705B (zh) * | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基***衍生物 |
| TWI481607B (zh) * | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| TWI485151B (zh) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
| EP2663565B1 (fr) | 2011-01-11 | 2017-03-15 | Sunovion Pharmaceuticals Inc. | Composés hétéroaryles et leurs procédés d'utilisation |
| JP2014510055A (ja) | 2011-02-18 | 2014-04-24 | アラーガン インコーポレイテッド | ホスホジエステラーゼ１０（ｐｄｅ１０ａ）阻害剤としての置換６，７−ジアルコキシ−３−イソキノリノール誘導体 |
| EP2758396B1 (fr) * | 2011-09-19 | 2017-03-29 | F. Hoffmann-La Roche AG | Composés de type triazolopyridine comme inhibiteurs de pde10a |
| WO2013127817A1 (fr) | 2012-02-27 | 2013-09-06 | H. Lundbeck A/S | Dérivés d'imidazole comme inhibiteurs de l'enzyme pde10a |
| WO2013178572A1 (fr) * | 2012-05-30 | 2013-12-05 | F. Hoffmann-La Roche Ag | Composés triazolo en tant qu'inhibiteurs de pde10 |
| WO2013192273A1 (fr) | 2012-06-19 | 2013-12-27 | Sunovion Pharmaceuticals Inc. | Composés hétéroaryles et leurs procédés d'utilisation |
| WO2014071044A1 (fr) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Dérivés de 6,7-dialcoxy-3-isoquinoline substitués à titre d'inhibiteurs de phosphodiestérase 10 (pde10a) |
| WO2014078216A1 (fr) * | 2012-11-15 | 2014-05-22 | Merck Sharp & Dohme Corp. | Cyclobutyl benzimidazoles en tant qu'inhibiteurs de pde10 |
| EP3074387B1 (fr) * | 2013-11-28 | 2017-11-08 | F.Hoffmann-La Roche Ag | Dérivés d'imidazole |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| CN114671874B (zh) * | 2021-08-30 | 2024-02-02 | 济南爱思医药科技有限公司 | 一种具有抗肿瘤活性的茶碱乙酸衍生物及其制备方法与应用 |
| WO2023064458A1 (fr) * | 2021-10-13 | 2023-04-20 | Yale University | Inhibiteurs sélectifs de jak2 et procédés d'utilisation |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1462521A (en) | 1974-02-11 | 1977-01-26 | Wyeth John & Brother Ltd | Triazole derivatives |
| GB8307865D0 (en) | 1983-03-22 | 1983-04-27 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
| US5571775A (en) | 1994-07-11 | 1996-11-05 | Dowelanco | N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides |
| US6699853B2 (en) | 1997-06-16 | 2004-03-02 | Hoechst Schering Agrevo Gmbh | 4-haloalkyl-3-heterocyclylpyridines, 4-haloalkyl-5-heterocyclyl-pyrimidines and 4-trifluoromethyl-3-oxadiazolylpyridines, processes for their preparation, compositions comprising them, and their use as pesticides |
| SE9802937D0 (sv) | 1998-09-01 | 1998-09-01 | Astra Pharma Prod | Novel compounds |
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| IL149106A0 (en) | 2001-04-20 | 2002-11-10 | Pfizer Prod Inc | Therapeutic use of selective pde10 inhibitors |
| FR2824065A1 (fr) | 2001-04-26 | 2002-10-31 | Neuro3D | Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations |
| JP2006509832A (ja) | 2002-10-30 | 2006-03-23 | ニューロ３デー | サイクリックヌクレオチドホスホジエステラーゼ阻害剤、その調製及び使用 |
| AU2004253694A1 (en) | 2003-06-30 | 2005-01-13 | 4Sc Ag | Novel pyrrolodihydroisoquinolines useful in the treatment of cancer |
| US20070105840A1 (en) | 2003-06-30 | 2007-05-10 | Altana Pharma Ag | Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
| WO2005012485A2 (fr) | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Procedes pour traiter le diabete, et les troubles associes, au moyen d'inhibiteurs des pde10a |
| CA2556413A1 (fr) | 2004-02-18 | 2005-09-09 | Pfizer Products Inc. | Derives tetrahydroisoquinolinyliques de quinazoline et d'isoquinoline |
| FR2870539B1 (fr) | 2004-05-19 | 2006-08-04 | Greenpharma Sa Sa | Nouvelles methodes et medicaments |
| EP1755611A1 (fr) | 2004-06-07 | 2007-02-28 | Pfizer Products Inc. | Inhibition de la phosphodiesterase 10 dans le traitement des etats pathologiques associes a l'obesite et au syndrome metabolique |
| US20060019975A1 (en) | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
| AU2005282721A1 (en) | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| NL2000397C2 (nl) * | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| US20080090834A1 (en) * | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| CN101495476A (zh) * | 2006-07-10 | 2009-07-29 | H.隆德贝克有限公司 | 6,7-二烷氧基喹唑啉、6,7-二烷氧基酞嗪和6,7-二烷氧基异喹啉的(3-芳基-哌嗪-1-基)、(2-芳基-吗啉-4-基)和(2-芳基-硫代吗啉-4-基)衍生物 |
| US7897619B2 (en) | 2007-07-17 | 2011-03-01 | Amgen Inc. | Heterocyclic modulators of PKB |
| GB0800411D0 (en) | 2008-01-10 | 2008-02-20 | Glaxo Group Ltd | Novel compounds |
| TWI485151B (zh) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
| TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| TWI487705B (zh) * | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基***衍生物 |
| CN103038229B (zh) * | 2010-05-26 | 2016-05-11 | 桑诺维恩药品公司 | 杂芳基化合物及其使用方法 |
-
2010
- 2010-12-13 TW TW099143441A patent/TWI487705B/zh not_active IP Right Cessation
- 2010-12-15 NZ NZ600365A patent/NZ600365A/xx not_active IP Right Cessation
- 2010-12-15 EP EP10797991.6A patent/EP2513106B1/fr active Active
- 2010-12-15 DK DK10797991.6T patent/DK2513106T3/da active
- 2010-12-15 CN CN201080064069.0A patent/CN102753550B/zh not_active Expired - Fee Related
- 2010-12-15 ES ES10797991.6T patent/ES2442179T3/es active Active
- 2010-12-15 GE GEAP201012784A patent/GEP20146201B/en unknown
- 2010-12-15 UA UAA201207980A patent/UA107950C2/uk unknown
- 2010-12-15 SI SI201030474T patent/SI2513106T1/sl unknown
- 2010-12-15 BR BR112012014486A patent/BR112012014486A2/pt not_active Application Discontinuation
- 2010-12-15 US US13/515,351 patent/US8501795B2/en not_active Expired - Fee Related
- 2010-12-15 RS RS20130588A patent/RS53101B/en unknown
- 2010-12-15 WO PCT/DK2010/050344 patent/WO2011072697A1/fr active Application Filing
- 2010-12-15 EA EA201290517A patent/EA021606B1/ru not_active IP Right Cessation
- 2010-12-15 MX MX2012006715A patent/MX2012006715A/es active IP Right Grant
- 2010-12-15 CA CA2783728A patent/CA2783728C/fr not_active Expired - Fee Related
- 2010-12-15 JP JP2012543477A patent/JP6035149B2/ja not_active Expired - Fee Related
- 2010-12-15 AU AU2010333438A patent/AU2010333438B2/en not_active Ceased
- 2010-12-15 PL PL10797991T patent/PL2513106T3/pl unknown
- 2010-12-15 KR KR1020127015379A patent/KR101779629B1/ko active IP Right Grant
- 2010-12-15 PT PT107979916T patent/PT2513106E/pt unknown
- 2010-12-15 SG SG2012043493A patent/SG181672A1/en unknown
- 2010-12-15 MA MA35064A patent/MA33923B1/fr unknown
- 2010-12-15 MY MYPI2012002595A patent/MY156520A/en unknown
- 2010-12-16 AR ARP100104669A patent/AR079496A1/es unknown
-
2012
- 2012-05-31 TN TNP2012000278A patent/TN2012000278A1/en unknown
- 2012-06-12 IL IL220328A patent/IL220328A/en not_active IP Right Cessation
- 2012-06-12 CR CR20120318A patent/CR20120318A/es unknown
- 2012-06-13 GT GT201200193A patent/GT201200193A/es unknown
- 2012-06-15 ZA ZA2012/04420A patent/ZA201204420B/en unknown
- 2012-06-15 CO CO12101114A patent/CO6602117A2/es active IP Right Grant
- 2012-06-15 DO DO2012000169A patent/DOP2012000169A/es unknown
-
2013
- 2013-04-23 HK HK13104921.1A patent/HK1177745A1/xx not_active IP Right Cessation
- 2013-06-20 US US13/922,371 patent/US8785653B2/en not_active Expired - Fee Related
- 2013-12-19 HR HRP20131210AT patent/HRP20131210T1/hr unknown
-
2014
- 2014-01-07 CY CY20141100012T patent/CY1116361T1/el unknown
- 2014-01-22 SM SM201400009T patent/SMT201400009B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA33923B1 (fr) | Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a | |
| MA37958B1 (fr) | Pde9i ayant un squelette imidazo pyrazinone | |
| MY152949A (en) | Novel phenylimidazole derivatives as pde10a enzyme inhibitors | |
| UA102693C2 (ru) | Производные фенилимидазола как ингибиторы фермента pde10a | |
| MA31447B1 (fr) | Nouveaux dérivés d'acide dicarboxylique utilisés comme agonistes du récepteur s1p1 | |
| TN2012000287A1 (en) | 2-arylimidazole derivatives as pde10a enzyme inhibitors | |
| MA33922B1 (fr) | Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a | |
| MA35404B1 (fr) | Composés pour le traitement de la toxicomanie | |
| MY163327A (en) | Imidazole derivatives as pde10a enzyme inhibitors | |
| MA35874B1 (fr) | Dérivés d'amide cycliques à utiliser en tant qu'inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase et utilisations de ceux-ci | |
| MA32108B1 (fr) | Derives d'indazole | |
| MA31761B1 (fr) | Nouveaux inhibiteurs de seh et leur utilisation | |
| MA35875B1 (fr) | Dérivés d'aza-adamantane et leurs utilisations | |
| MA34736B1 (fr) | Dérivé d'imidazole en tant qu'inhibiteurs de l'enzyme pde10a | |
| MA35882B1 (fr) | Inhibiteurs de pde9 comprenant un squelette imidazotriazinone | |
| TN2010000111A1 (fr) | Nouveaux sels d'addition d'inhibiteurs d'enzyme de conversion de l'angiotensine a des acides donneurs de no, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| MA35860B1 (fr) | Dérivés de quinoléine en tant qu'inhibiteurs d'enzyme pde10a | |
| TN2010000387A1 (fr) | Derives d'indazole | |
| MA34196B1 (fr) | Dérivés d'imidazole condensés comme antagonistes de trpv3 | |
| MA31356B1 (fr) | Utilisation d'inhibiteurs de la hdac pour le traitement des cancers gastro-intestinaux | |
| MA34198B1 (fr) | Dérivés de chroménone convenant comme antagonistes trpv3 | |
| MA34195B1 (fr) | Derives du chromane comme modulateurs de trpv3 | |
| MA37836B1 (fr) | Antagonistes du récepteur 5-ht3 | |
| TN2010000612A1 (fr) | Derives de triazole utiles pour le traitement de maladie | |
| MA34201B1 (fr) | Carboxamides d'imidazole fusionnes utilises en tant que modulateurs du trpv3 |